The company takes advantage of the rapidly expanding Asian pharmaceutical market
Biopharma company Zeta Group has taken a majority stake in Biotree, the Indian engineering and plant construction specialist.
Biotree will be integrated into ZETA's global engineering and delivery network and complete the service portfolio in the Asian region.
This comes as the Asian biopharmaceutical market expands rapidly with an annual growth rate of 13%.
“Together, we will intensify our market development in the Asian region and further expand services for our customers, particularly in India and Southeast Asia," said Andreas Marchler, CEO of ZETA Group.
ZETA thus consistently implementing the strategy of offering high-quality end-to-end solutions for the pharmaceutical and biotech industry globally
“We are pooling our resources and skills: global presence with engineering, plant construction, and automation hubs in Europe, the USA, and Asia. This is paired with in-depth knowledge of local market requirements," said Dr Anil Paul Kariath, CEO of Biotree.
"It is very important for us to offer our customers in all parts of the world the same expertise and high quality in the fields of engineering, plant construction, automation, and digitalisation. With Biotree, we now have an Asian partner on board that fulfils all of these requirements excellently. ZETA is thus consistently implementing the strategy of offering high-quality end-to-end solutions for the pharmaceutical and biotech industry globally, from engineering, construction, automation, digitisation to qualification," added Andreas Marchler.